Cipla Reports 55% Decline in Q4 Net Profit to Rs 555 Crore Amid Revenue Slump and Increased Expenses

Cipla Reports Sharp Decline in Earnings for Fourth Quarter of FY26

Drugmaker Cipla reported a significant decline in earnings for the fourth quarter of FY26, with consolidated net profit falling 55 percent year-on-year to Rs 554.6 crore. This decline was driven by a decrease in revenue and an increase in expenses, which put pressure on the company's bottomline.

Cipla's revenue from operations fell 2.8 percent on-year to Rs 6,541.2 crore during the January-March quarter, while total expenses rose 8.5 percent to Rs 5,982.3 crore. The weaker topline performance coupled with higher costs significantly eroded profitability during the quarter.

The company also announced an impairment charge of around Rs 42.02 crore in respect of associates due to changes in certain business conditions and market dynamics. This charge was included in the quarterly and annual financial results.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Despite the decline in earnings, the Board of Directors recommended a final dividend of Rs 13 per equity share for the financial year ended March 31, 2026. Subject to shareholder approval at the annual general meeting, the dividend will be paid within 30 days of the AGM. The record date for determining shareholder eligibility has been fixed as June 5, 2026.

In a statement, Achin Gupta, MD and Global CEO, Cipla, highlighted the company's progress in focused markets. Cipla recorded its highest-ever yearly revenue of Rs 28,163 crore in FY26, reflecting the strength of its core businesses despite certain markets facing near-term challenges.

The decline in earnings was largely driven by weakness in the North America business, which saw revenue fall 26 percent year-on-year to Rs 1,414 crore. However, the drop was offset by strong performance in other geographies, with the India business growing 15 percent, Africa rising 21 percent, and emerging markets showing resilience despite geopolitical challenges.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

For the full year, the company reported revenue of Rs 28,163 crore, up 2 percent year-on-year, while net profit fell to Rs 3,879 crore from Rs 5,273 crore in the previous fiscal. EBITDA margin for FY26 also declined to 21 percent from 25.9 percent in FY25, indicating broader pressure on profitability.

Cipla's India business remained a key growth driver, supported by strong momentum in branded prescription, trade generics, and consumer health segments. The company's chronic therapies, including respiratory, cardiac, and anti-diabetes, continued to deliver double-digit growth, with flagship brands maintaining leadership positions.

In the US, the company continued to focus on its differentiated portfolio and pipeline execution, including progress on complex generics and regulatory approvals such as the first AB-rated gVentolin inhaler, expected to support growth in coming quarters.

Looking ahead, management said the focus will remain on sustaining growth across key markets, strengthening flagship brands, and advancing pipeline investments, while also addressing regulatory matters to support long-term performance.